ERAS-007

Description

ERAS-007 is an experimental medication currently being studied in clinical trials for certain types of advanced gastrointestinal cancers, including colorectal cancer (CRC). It is being investigated as a potential treatment option, often in combination with other established cancer therapies like cetuximab, encorafenib, and palbociclib. The trials are specifically looking at patients whose CRC has certain genetic mutations, such as BRAF V600E or KRAS/NRAS mutations. This drug is in the early stages of testing (Phase 1), meaning researchers are primarily focused on determining the safest dose and how patients respond to it. It is not yet approved for use in CRC or any other cancer.

Mechanism of Action

ERAS-007 is being studied to see if it can help treat cancers that have specific genetic mutations. In the trials for CRC, it is being tested in combination with other drugs. For patients with BRAF V600E mutations, it's being combined with encorafenib and cetuximab. For patients with KRAS or NRAS mutations, it's being combined with palbociclib. The specific way ERAS-007 works at a molecular level is still under investigation as part of these clinical trials.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials